• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Charles River Laboratories International Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    12/13/24 4:42:51 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $CRL alert in real time by email
    false 0001100682 0001100682 2024-12-13 2024-12-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    ____________________________

     

    FORM 8-K 

    ____________________________ 

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    December 13, 2024

    Date of Report (Date of earliest event reported) 

    ____________________________

     

    CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

    (Exact name of registrant as specified in its charter) 

    ____________________________

     

    001-15943

    (Commission File Number)

     

    Delaware 06-1397316
    (State of Incorporation) (I.R.S. Employer Identification No.)

     

    251 Ballardvale Street

    Wilmington, Massachusetts 01887

    (Address of Principal Executive Offices) (Zip Code)

     

    781-222-6000

    (Registrant’s Telephone Number, including Area Code)

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common stock, $0.01 par value CRL New York Stock Exchange

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

    ITEM 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    On December 13, 2024, Charles River Laboratories International, Inc. (“Charles River”) amended and restated its existing credit agreement with certain financial institutions and JPMorgan Chase Bank, N.A., as administrative agent (the “Tenth Amended and Restated Credit Agreement”). The Tenth Amended and Restated Credit Agreement (1) extends the maturity date for the facilities, (2) reduces the aggregate revolving commitments thereunder from $3 billion to $2 billion, (3) incorporates Charles River Laboratories, Inc. (“CRL”), a direct subsidiary of Charles River, as a borrower under the credit agreement and (4) makes certain other amendments to certain other covenants and terms. Subject to certain customary exceptions, the obligations of Charles River under the Tenth Amended and Restated Credit Agreement are guaranteed by CRL, and are secured by substantially all of the assets of Charles River, CRL and any future material domestic subsidiaries of Charles River, including a pledge of 100% of the capital stock of CRL and any future material domestic subsidiaries of Charles River, and 65% of the capital stock of certain first-tier material foreign subsidiaries of Charles River and the guarantors.

     

    The Tenth Amended and Restated Credit Agreement provides for up to approximately $2 billion in financing pursuant to a revolving credit facility. The revolving facility is available in U.S. dollars to Charles River and CRL and in euros and sterling to Charles River and certain of its subsidiaries based in the United Kingdom, the Netherlands and Luxembourg (the “Multicurrency Revolving Facility”). The revolving facility matures on December 13, 2029, and requires no scheduled payment before that date. The interest rates applicable to revolving loans under the credit agreement are equal to (A) for revolving loans denominated in U.S. dollars, at Charles River’s option, either the base rate (which is the higher of (1) the prime rate, (2) the federal funds rate plus 0.50%, or (3) the one-month adjusted SOFR rate plus 1%) or the adjusted Term SOFR rate, (B) for revolving loans denominated in euros, the adjusted EURIBOR rate and (C) for revolving loans denominated in sterling, the daily simple RFR rate, in each case, plus an interest rate margin based upon Charles River’s leverage ratio.

     

    The Tenth Amended and Restated Credit Agreement requires that Charles River comply with an interest coverage ratio test and a leverage ratio test. In addition, the Tenth Amended and Restated Credit Agreement includes negative covenants that will, subject to significant exceptions, limit the ability of Charles River and its subsidiaries to:

     

    •incur, assume, or permit to exist additional indebtedness or guarantees;

     

    •incur liens;

     

    •make investments and loans;

     

    •engage in mergers, acquisitions, and asset sales;

     

    •enter into agreements limiting subsidiary distributions;

     

    •engage in certain transactions with affiliates, and

     

    •alter the business that they conduct.

     

    The Tenth Amended and Restated Credit Agreement also contains certain customary representations and warranties, affirmative covenants, and events of default.

     

    The Tenth Amended and Restated Credit Agreement is attached hereto as Exhibit 10.1 and incorporated into this Item 2.03 by reference.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    10.1 Tenth Amended and Restated Credit Agreement, dated as of December 13, 2024, among Charles River Laboratories International, Inc., the Subsidiary Borrowers party thereto, the lenders party thereto, JPMorgan Chase Bank, N.A. as administrative agent, and the other agents party thereto.
       
    104  Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: December 13, 2024 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
      (Registrant)
         
         
      By: /s/ Madeline Moore
        Name: Madeline Moore
        Title: Assistant Secretary

      

     

     

    Get the next $CRL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRL

    DatePrice TargetRatingAnalyst
    12/15/2025$225.00Neutral → Buy
    BofA Securities
    11/17/2025Hold → Buy
    Argus
    11/6/2025$199.00Neutral → Outperform
    Robert W. Baird
    10/6/2025Mkt Perform → Outperform
    William Blair
    10/2/2025$195.00Equal Weight → Overweight
    Barclays
    9/9/2025$195.00Hold → Buy
    Jefferies
    7/9/2025$200.00Neutral → Buy
    Citigroup
    5/23/2025$182.00Neutral → Buy
    Redburn Atlantic
    More analyst ratings

    $CRL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Corporate Executive VP & COO Girshick Birgit gifted 328 shares (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/5/26 5:18:17 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chairman, President and CEO Foster James C was granted 16,796 shares, increasing direct ownership by 6% to 279,693 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:42:20 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX

    NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, April 6, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.  Kristen Scholer delivers the pre-market update on April 6thEquities rise Monday morning after a report indicates a push towards a ceasefire with Iran.The NYSE is partnering with leading AI conference HumanX at the Moscone Center in San Francisco this week and will have Ashley Mastronardi on the ground speaking to those transforming the space.James Foster, Chairman, President,

    4/6/26 8:55:00 AM ET
    $CRL
    $ICE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Charles River Laboratories to Present at TD Cowen and Barclays Conferences

    Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, at 9:50 a.m. ET; and Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, at 10:00 a.m. ET. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presenta

    3/2/26 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Provides Update on Planned Divestitures

    – Announces Signing of Definitive Agreements to Divest the CDMO and Cell Solutions Businesses and Certain European Discovery Services Assets – – Updates 2026 Financial Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that it has signed definitive agreements to sell certain European Discovery Services assets as well as the CDMO and Cell Solutions businesses in separate transactions. James C. Foster, Chair, President and Chief Executive Officer, said, "We are pleased to announce these planned divestitures today to demonstrate our continued progress on the actions outlined as part of the comprehensive strategic review conducted last year. We have decid

    2/25/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Corp Strategy & Develop Laplume Joseph W bought $4,364 worth of shares (25 units at $174.54), increasing direct ownership by 0.09% to 27,448 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    3/4/26 4:39:28 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chairman, President and CEO Foster James C bought $1,002,436 worth of shares (6,075 units at $165.01), increasing direct ownership by 3% to 183,639 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:41:25 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Corporate Executive VP & COO Girshick Birgit bought $249,250 worth of shares (1,514 units at $164.63), increasing direct ownership by 3% to 55,058 units (SEC Form 4)

    4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)

    2/21/25 4:38:37 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    SEC Filings

    View All

    SEC Form DEF 14A filed by Charles River Laboratories International Inc.

    DEF 14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    3/31/26 7:50:58 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Charles River Laboratories International Inc.

    SCHEDULE 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    3/26/26 5:15:43 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)

    2/25/26 7:34:10 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Charles River upgraded by BofA Securities with a new price target

    BofA Securities upgraded Charles River from Neutral to Buy and set a new price target of $225.00

    12/15/25 9:01:39 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by Argus

    Argus upgraded Charles River from Hold to Buy

    11/17/25 9:37:40 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Charles River from Neutral to Outperform and set a new price target of $199.00

    11/6/25 8:40:21 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Charles River Laboratories International Inc.

    SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    11/8/24 10:52:38 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13G/A filed by Charles River Laboratories International Inc.

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    10/22/24 3:24:03 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by Charles River Laboratories International Inc. (Amendment)

    SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)

    2/13/24 5:01:02 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Financials

    Live finance-specific insights

    View All

    Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

    – Fourth-Quarter Revenue of $994.2 Million and Full-Year Revenue of $4.02 Billion – – Fourth-Quarter GAAP Loss per Share of $(5.62) and Non-GAAP Earnings per Share of $2.39 – – Full-Year GAAP Loss per Share of $(2.91) and Non-GAAP Earnings per Share of $10.28 – – Provides 2026 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth quarter and full-year 2025 and provided guidance for 2026. For the quarter, revenue was $994.2 million, a decrease of 0.8% from $1,002.5 million in the fourth quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.9%, and the divestiture of a small Safety Assessm

    2/18/26 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

    Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2025 financial results and provide 2026 guidance on Wednesday, February 18th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 18th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi

    1/21/26 4:30:00 PM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces Third-Quarter 2025 Results

    – Third-Quarter Revenue of $1.00 Billion – – Third-Quarter GAAP Earnings per Share of $1.10 and Non-GAAP Earnings per Share of $2.43 – – Updates 2025 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the third quarter of 2025. For the quarter, revenue was $1.00 billion, a decrease of 0.5% from $1.01 billion in the third quarter of 2024. The impact of foreign currency translation increased reported revenue by 1.3%, and the divestiture of a small Safety Assessment site in 2024 reduced reported revenue by 0.2%. Excluding the effect of these items, revenue declined 1.6% on an organic basis. On a segment basis, lower revenue in the Discovery

    11/5/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $CRL
    Leadership Updates

    Live Leadership Updates

    View All

    Charles River Laboratories Announces Executive Appointments

    Glenn G. Coleman Will Join Charles River as Corporate Executive Vice President and Chief Financial Officer Kerry Dailey Will Join Charles River as Corporate Senior Vice President and Chief Legal Officer Charles River Laboratories International, Inc. (NYSE:CRL) today announced two executive appointments: Glenn G. Coleman has been named the Company's next Chief Financial Officer and Kerry Dailey has been named to the newly-created position of Chief Legal Officer. Birgit Girshick, Corporate Executive Vice President, Chief Operating Officer and incoming Chief Executive Officer, commented, "We are very pleased to welcome Kerry Dailey and Glenn Coleman in two key executive roles, as we stre

    2/18/26 7:01:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

    – Board Approves Appointment of Four New Directors – – Strategic Planning and Capital Allocation Committee of the Board to Conduct Comprehensive Strategic Review of the Company's Business – – Enters into Cooperation Agreement with Elliott Investment Management – Charles River Laboratories International, Inc. (NYSE:CRL) today announced that four new directors will join its Board of Directors and that four long-time members of the Board will not seek re-election at the 2025 Annual Meeting of Shareholders. The Company also announced changes to its Board committees and a strategic review of the Company's business focused on enhancing long-term value for shareholders. Charles River's Board o

    5/7/25 7:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery

    Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow

    7/24/24 8:00:00 AM ET
    $CRL
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care